ARCHIVES

Vaccine Increases PFS by 4 Months In Phase II Per-Protocol Analysis

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Recommend Approval Of Leucovorin, Hexamethylmelamine

June 16, 1989

Three NCAB Members Say They Cannot Offer “Strong Endorsement” Of P-4 Trial.

June 15, 2007

ASCO Annual Report Names Significant Clinical Research Advances Of Past Year

December 25, 2009

Bypass Budget Seeks Double Funding for Breast Cancer Research

November 6, 1992

Bush Limits Drug Company Efforts To Block Generics

October 25, 2002

Groups Accepting Need for More Collaboration, NCI Backs Away From Drastic Structural Changes

July 11, 1986